Abiraterone acetate/enzalutamide
- PDF / 169,480 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 29 Downloads / 173 Views
1 S
Drug resistance: case report In a case report, an 83-year-old man was described, who developed drug resistance during treatment with abiraterone acetate and enzalutamide for metastatic castration-resistant prostate cancer (mCRPC). The man, who had mCRPC, initially presented with a lymphadenopathy and bladder mass. At presentation, his prostate-specific antigen (PSA) level was 317 ng/mL. Biopsy of bladder mass revealed a Gleason score of 5+4 prostate adenocarcinoma. Hence, he started receiving androgen deprivation therapy (ADT) with enzalutamide and abiraterone acetate [routes and dosages not stated]. He also underwent tumour sequencing, which showed microsatellite instability (MSI) and hypermutation related to biallelic MSH2 mutation (exons 1–6+EPCAM deletion). Germline testing for EPCAM/MSH2 was negative. Within 2 months of ADT therapy, his prostate cancer became treatment resistant and was refractory to enzalutamide and abiraterone acetate. Hence, the man started receiving pembrolizumab as a third-line treatment. However, he did not attain a significant clinical response. Sokolova AO, et al. Complexities of next-generation sequencing in solid tumors: Case studies. Journal of the National Comprehensive Cancer Network 18: 1150-1155, No. 9, 803520926 Sep 2020. Available from: URL: http://doi.org/10.6004/JNCCN.2020.7569
0114-9954/20/1834-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved
Reactions 12 Dec 2020 No. 1834
Data Loading...
